Cargando…

Exploratory analysis of comparative clinical trials used for marketing approval in patients with type 2 diabetes in Japan

BACKGROUND/OBJECTIVES: The results of phase 2 and 3 clinical trials, which justify decisions regarding marketing approval for new drugs, are used for comparison of drugs in the post-marketing phase. A number of meta-analyses of approved antidiabetics have been performed, but the heterogeneity of tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaneko, Reina, Ono, Shunsuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329034/ https://www.ncbi.nlm.nih.gov/pubmed/30671243 http://dx.doi.org/10.1177/2050312118823407

Ejemplares similares

Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan
por: Okubo, TK, et al.
Publicado: (2017)

Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval
por: Harada, Kenji, et al.
Publicado: (2019)

Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan
por: Kubota, Sachie, et al.
Publicado: (2016)

Quality evaluation of investigator‐initiated trials using post‐approval cancer drugs in Japan
por: Kondo, Shunsuke, et al.
Publicado: (2017)

Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials
por: Doua, Yorokpa Joachim, et al.
Publicado: (2019)

Exploratory Analysis of the Factors Associated With Success Rates of Confirmatory Randomized Controlled Trials in Cancer Drug Development
por: Wu, Can, et al.
Publicado: (2020)

Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval
por: Song, Lin, et al.
Publicado: (2022)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Utilization and Comparative Effectiveness of Caspofungin and Voriconazole Early after Market Approval in the U.S
por: Ascioglu, Sibel, et al.
Publicado: (2014)

Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza
por: Mawatari, Momoko, et al.
Publicado: (2019)

Factors Affecting Drug‐Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan
por: Asano, Kunihito, et al.
Publicado: (2017)

Comparing and contrasting different herbal products intended for the management of obesity approved in the Palestinian markets
por: Eid, Ahmad M., et al.
Publicado: (2023)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Drug-loaded erythrocytes: on the road toward marketing approval
por: Bourgeaux, Vanessa, et al.
Publicado: (2016)

Lifecycle management of orphan drugs approved in Japan
por: Seki, Kiyoshi, et al.
Publicado: (2022)

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
por: Maeda, Hideki, et al.
Publicado: (2023)

Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post‐approval in Japan
por: Saito, Rieko, et al.
Publicado: (2023)

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals
por: Hao, Jing, et al.
Publicado: (2015)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
por: Namiot, Eugenia D., et al.
Publicado: (2023)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada, Eiji, et al.
Publicado: (2015)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

The effect size, study design, and development experience in commercially sponsored studies for new drug applications in approved drugs
por: Fukunaga, Satoshi, et al.
Publicado: (2014)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Analysis of Safety-Related Regulatory Actions for New Drugs in Japan by Nature of Identified Risks
por: Fujikawa, Makoto, et al.
Publicado: (2017)

An open science pathway for drug marketing authorization—Registered drug approval
por: Naudet, Florian, et al.
Publicado: (2021)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
por: Fazeli Farsani, Soulmaz, et al.
Publicado: (2019)

Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
por: Hagihara, Mao, et al.
Publicado: (2012)

A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States
por: Hoshino, Yuko, et al.
Publicado: (2022)

Repurposing the PDMA-approved drugs in Japan using an insect model of staphylococcal infection
por: Miyashita, Atsushi, et al.
Publicado: (2022)

SuperDRUG2: a one stop resource for approved/marketed drugs
por: Siramshetty, Vishal B, et al.
Publicado: (2018)

Covid-19 vaccine approvals and stock market returns: The case of Chinese stocks
por: Ho, Ken C., et al.
Publicado: (2022)

Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021)

A survey of clinical physician's perceptions of stigma and advocacy in patients with type 2 diabetes in Kanagawa, Japan
por: Matsuzawa, Yoko, et al.
Publicado: (2022)

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
por: Sato, Akinori
Publicado: (2012)

Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic
por: Maeda, Hideki
Publicado: (2021)

Japan's COVID‐19 treatment strategy: An examination of approved oral medications
por: Higuchi, Yuka, et al.
Publicado: (2023)

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data
por: Lambert, Jérôme, et al.
Publicado: (2023)

Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-
por: Konishi, Akihide, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7l8m2pndvica56od2u170v1o49